Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 135.00Impact Factor 2024: 2.2
Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion.
The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.
Authors: Zhong, Hua | Yang, Jun | Zhang, Bin | Wang, Xiaofang | Pei, Lihong | Zhang, Lei | Lin, Zhiqiang | Wang, Yanan | Wang, Chengbin
Article Type: Research Article
Abstract: Breast cancer is the most common malignancy in women which increases gradually all over the world. LncRNA GACAT3 has been found to be increased in gastric cancer and associated with tumor malignancy. However, whether GACAT3 plays a role in the regulation of breast cancer is not known. In the present study, we found that GACAT3 expression was increased in breast cancer tissues and cells compared with adjacent normal tissues and normal cells. High GACAT3 expression was correlated with the poor prognosis of breast cancer patients. GACAT3 and cyclin D2 (CCND2) contained a binding site of miR-497. miR-497 was decreased in …breast cancer tissues and cells compared with adjacent normal tissues and normal cells. Low miR-497 expression was correlated with the poor prognosis of breast cancer patients. In breast cancer tissues, the expression of miR-497 was negatively correlated with GACAT3. Downregulation of GACAT3 increased miR-497 expression. miR-497 mimic reduced the luciferase of GACAT3 and CCND2. Anti-miR-497 reversed the effects of GACAT3 downregulation. We also found that GACAT3 may act as a ceRNA for miR-497, enhancing the expression of CCND2. In conclusion, GACAT3 promotes breast cancer malignancy by sponging miR-497, leading to the enhancement of its endogenous target CCND2. These results suggest that GACAT3/miR-497/CCND2 is a potential therapeutic target and biomarker for breast cancer. Show more
Keywords: Breast cancer, CCND2, lncRNA GACAT3, malignancy, miR-497
DOI: 10.3233/CBM-181354
Citation: Cancer Biomarkers, vol. 22, no. 4, pp. 787-797, 2018
Authors: Huang, Yiqun | Zou, Yong | Lin, Luhui | Ma, Xudong | Chen, Hongpu
Article Type: Research Article
Abstract: BACKGROUND: MicroRNA-34a (miR-34a), as a tumor-suppressive miRNA, has been found to induce cell apoptosis in acute myeloid leukemia (AML). However, the diagnostic and prognostic significance of miR-34a in AML remains largely unknown. OBJECTIVE: We aimed to explore its associations with clinical characteristics and prognosis of AML patients. METHODS: This study detected serum miR-34a level in 117 diagnosed AML patients and 60 control subjects by using qRT-PCR, and results were compared to clinical features and patient outcome. Since cytogenetically-normal AML (CN-AML) has a good uniformity of cytogenetics and provides a perfect platform for detection of AML biomarkers, we …further analyzed miR-34a expression in 56 CN-AML subjects. RESULTS: We found that miR-34a was significantly downregulated in AML and CN-AML patients. MiR-34a underexpression was commonly observed in AML patients with intermediate/poor risk cytogenetic, and M5 subtype. ROC analysis demonstrated that serum miR-34a could well identify AML/CN-AML patients from healthy individuals. More importantly, miR-34a expression was found negatively correlated with aggressive clinical variable, and served as an independent prognostic indicator. In addition, AML/CN-AML patients with low miR-34a expression displayed shorter overall and recurrence free survival. CONCLUSIONS: Altogether, miR-34a might have an application as a diagnostic and prognostic indicator for AML patients. Show more
Keywords: miR-34a, biomarker, acute myeloid leukemia, diagnosis, prognosis
DOI: 10.3233/CBM-181381
Citation: Cancer Biomarkers, vol. 22, no. 4, pp. 799-805, 2018
Authors: Jia, Tao | Zhang, Run | Zhu, Hua-Yuan | Liang, Jin-Hua | Wang, Li | Wu, Wei | Cao, Lei | Li, Jian-Yong | Xu, Wei
Article Type: Research Article
Abstract: BACKGROUND: Peripheral blood absolute monocyte count (AMC) and lymphocyte to monocyte ratio (LMR) have strong prognostic value in various forms of lymphomas. It was found that higher AMC and lower LMR were associated with poor prognosis in B cell lymphoma. However, their prognostic significance in systemic anaplastic large cell lymphoma (sALCL) remained to be determined. OBJECTIVE: This study was aimed at investigating the prognostic significance of AMC and LMR in sALCL. METHODS: A total of 29 newly diagnosed patients with sALCL were retrospectively included in study, prognostic significance of AMC, LMR, performance status …(PS), international prognostic index (IPI), prognostic index for T-cell lymphomas (PIT) and other indicators were analyzed. RESULTS: Univariate analysis showed high AMC, LMR < 2.5, PS ⩾ 2, extranodal involvement, no response to treatment and B symptoms predicted inferior PFS; LMR < 2.5, no response to treatment, elevated LDH, IPI ⩾ 3, PIT ⩾ 2 and PS ⩾ 2 predicted inferior OS. High AMC, PS ⩾ 2 were independent prognostic factors for PFS; PS ⩾ 2, no response to treatment and elevated LDH were independent prognostic factors for OS. CONCLUSIONS: AMC was an independent prognostic factor for PFS in sALCL, and LMR < 2.5 also indicated poor prognosis. Show more
Keywords: Anaplastic large cell lymphoma, absolute monocyte count, absolute lymphocyte count, lymphocyte to monocyte ratio, prognosis
DOI: 10.3233/CBM-181505
Citation: Cancer Biomarkers, vol. 22, no. 4, pp. 807-813, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl